ADELA | Home

Adela Bio | Toronto, San Fransisco | A breakthrough approach to cancer detection [elderly couple smiling]

Adela is developing best-in-class technology to accelerate the diagnosis and improve the management of cancer through blood tests

Adela's platform can be applied across the cancer continuum

With a single, scalable platform, Adela is poised to address the unmet need broadly across multiple cancers and applications

Detect minimal residual disease (MRD) following surgery to guide use of adjuvant treatment and monitor for recurrence

Monitor for response in patients receiving immunotherapy

Early identification of multiple types of cancer for screening and detection

Adela’s mission is to deliver innovative and accessible blood tests that harness biology to transform cancer care and improve well-being.

Adela Bio | Toronto, San Fransisco | A breakthrough approach to cancer detection [father and child playing guitar]

RECENT UPDATES

April 28, 2025

Adela Presents Data Demonstrating Ability of Tissue-Free MRD Test to Predict Recurrence in Lung Cancer at the American Association for Cancer Research Annual Meeting 2025

April 11, 2025

Adela’s Co-Founder & Chief Scientific Officer, Dr. Daniel De Carvalho, Receives 2025 Canada Gairdner Momentum Award Recognizing World-Renowned Scientists for Exceptional Scientific Research Contributions with Continued Potential for Impact on Human Health

November 14, 2024

Adela to Present Biological Insights into its Tissue-Agnostic Assay for Molecular Residual Disease Detection at the AACR Special Conference in Cancer Research